MCID: LRG001
MIFTS: 51

Large Cell Carcinoma malady

Categories: Cancer diseases, Genetic diseases, Respiratory diseases, Skin diseases, Rare diseases

Aliases & Classifications for Large Cell Carcinoma

Aliases & Descriptions for Large Cell Carcinoma:

Name: Large Cell Carcinoma 12 14
Carcinoma, Large Cell 42 69
Carcinoma Large Cell 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4552
MeSH 42 D018287
NCIt 47 C3780
SNOMED-CT 64 189551005 22687000
UMLS 69 C0206704

Summaries for Large Cell Carcinoma

Disease Ontology : 12 A carcinoma that is composed of large, monotonous rounded or overtly polygonal-shaped cells with abundant cytoplasm.

MalaCards based summary : Large Cell Carcinoma, also known as carcinoma, large cell, is related to lung large cell carcinoma and large cell carcinoma with rhabdoid phenotype. An important gene associated with Large Cell Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Developmental Biology and PI3K-Akt signaling pathway. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include lung, thyroid and brain, and related phenotypes are Decreased viability and cellular

Related Diseases for Large Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 6
Basal Cell Carcinoma 5 Basal Cell Carcinoma 4
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
id Related Disease Score Top Affiliating Genes
1 lung large cell carcinoma 12.3
2 large cell carcinoma with rhabdoid phenotype 12.1
3 thymus large cell carcinoma 12.0
4 lung occult large cell carcinoma 11.9
5 pleomorphic carcinoma 11.1
6 lung mixed small cell and squamous cell carcinoma 10.9
7 peroneal nerve paralysis 10.3 CHGA SYP
8 infiltrating renal pelvis transitional cell carcinoma 10.3 ENO2 SYP
9 sm-ahnmd 10.3 CHGA ENO2
10 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.3 FGFR1 PDGFRA
11 brain stem ependymoma 10.3 CHGA SYP
12 skeletal-extraskeletal angiomatosis 10.3 ENO2 SYP
13 extrahepatic biliary papillomatosis 10.3 CHGA SYP
14 uterine corpus sarcoma 10.3 ENO2 NCAM1
15 radiculopathy 10.3 KRT7 TP63
16 gastrointestinal system benign neoplasm 10.3 CHGA ENO2 NKX2-1
17 thymus small cell carcinoma 10.3 CHGA ENO2 SYP
18 prolactin producing pituitary tumor 10.3 CHGA ENO2 SYP
19 perineural angioma 10.3 CHGA ENO2 SYP
20 piussan lenaerts mathieu syndrome 10.2 CHGA ENO2 SYP
21 congenital muscular dystrophy with hyperlaxity 10.2 ENO2 NKX2-1 SYP
22 cavernous hemangioma of face 10.2 CHGA NKX2-1 SYP
23 autosomal dominant proximal renal tubular acidosis 10.2 FGFR1 PDGFRA
24 pediculus humanus corporis infestation 10.2 CHGA ENO2 SYP
25 mitochondrial complex ii deficiency 10.2 CHGA NKX2-1 SYP
26 ampulla of vater mucinous adenocarcinoma 10.2 CHGA ENO2 SYP
27 bone marrow cancer 10.2 CHGA NKX2-1 SYP
28 cardioauditory syndrome of sanchez cascos 10.2 CHGA ENO2 SYP
29 clear cell variant infiltrating bladder urothelial carcinoma 10.2 CHGA ENO2 SYP
30 synovitis 10.2 KRT7 SYP
31 colorectal cancer 1 10.2 CHGA ENO2 SYP
32 diabetes persistent mullerian ducts 10.2 CHGA ENO2 SYP
33 epithelioid malignant peripheral nerve sheath tumor 10.2 CHGA SYP
34 childhood medulloblastoma 10.2 ENO2 SYP TP63
35 zollinger-ellison syndrome 10.2 CHGA ENO2 SYP
36 chromophil adenoma of the kidney 10.2 ENO2 NKX2-1
37 malignant granular cell myoblastoma 10.2 CHGA PTHLH
38 intrahepatic bile duct adenoma 10.2 NCAM1 SYP
39 thymoma 10.2 ENO2 KRT7 SYP
40 duodenal obstruction 10.2 KRT7 NKX2-1 SYP
41 ampullary signet ring cell adenocarcinoma 10.2 ENO2 NCAM1 SYP
42 neutropenia, severe congenital, 5, autosomal recessive 10.2 CHGA ENO2 NKX2-1
43 cavernous hemangioma of colon 10.2 ENO2 NCAM1
44 vulvar alveolar soft part sarcoma 10.2 ENO2 NCAM1 SYP
45 adenocarcinoma 10.2
46 vaginal villous adenoma 10.2 CHGA KRT7 SYP
47 struma ovarii 10.2 CHGA KRT7 SYP
48 peeling skin syndrome 10.2 CHGA NCAM1 SYP
49 hemolytic anemia 10.2 CHGA ENO2 NKX2-1 SYP
50 eccrine papillary adenocarcinoma 10.1 CHGA PTHLH SYP

Graphical network of the top 20 diseases related to Large Cell Carcinoma:



Diseases related to Large Cell Carcinoma

Symptoms & Phenotypes for Large Cell Carcinoma

GenomeRNAi Phenotypes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.8 EGFR
2 Decreased viability GR00173-A 9.8 PDGFRA
3 Decreased viability GR00221-A-1 9.8 EGFR FGFR1 KIT PDGFRA ROS1
4 Decreased viability GR00221-A-2 9.8 FGFR1 ROS1
5 Decreased viability GR00221-A-3 9.8 PDGFRA
6 Decreased viability GR00221-A-4 9.8 EGFR PDGFRA
7 Decreased viability GR00301-A 9.8 KIT
8 Decreased viability GR00342-S-1 9.8 ROS1
9 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 8.8 FGFR1 PDGFRA ROS1

MGI Mouse Phenotypes related to Large Cell Carcinoma:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 EGFR ENO2 FGFR1 KIT KRT7 NCAM1
2 behavior/neurological MP:0005386 10.33 ENO2 FGFR1 KIT NCAM1 NKX2-1 PDGFRA
3 cardiovascular system MP:0005385 10.28 CHGA EGFR FGFR1 KIT NKX2-1 PDGFRA
4 growth/size/body region MP:0005378 10.28 CHGA EGFR ENO2 FGFR1 KIT NKX2-1
5 homeostasis/metabolism MP:0005376 10.26 NKX2-1 PDGFRA PTHLH STK11 TP63 UCHL1
6 mortality/aging MP:0010768 10.26 CHGA DSC3 EGFR FGFR1 KIT NCAM1
7 digestive/alimentary MP:0005381 10.21 EGFR FGFR1 KIT NKX2-1 PDGFRA PTHLH
8 endocrine/exocrine gland MP:0005379 10.2 TP63 CHGA EGFR FGFR1 KIT NKX2-1
9 craniofacial MP:0005382 10.17 EGFR ENO2 FGFR1 KIT PDGFRA PTHLH
10 nervous system MP:0003631 10.17 EGFR ENO2 FGFR1 KIT NCAM1 NKX2-1
11 integument MP:0010771 10.16 DSC3 EGFR FGFR1 KIT PDGFRA PTHLH
12 limbs/digits/tail MP:0005371 10.04 EGFR FGFR1 KIT PDGFRA PTHLH TP63
13 normal MP:0002873 10.02 DSC3 EGFR FGFR1 KIT NKX2-1 PDGFRA
14 renal/urinary system MP:0005367 10.02 CHGA EGFR FGFR1 KIT KRT7 PDGFRA
15 no phenotypic analysis MP:0003012 10.01 EGFR FGFR1 KIT NKX2-1 PDGFRA ROS1
16 reproductive system MP:0005389 9.96 CHGA EGFR FGFR1 KIT NKX2-1 PDGFRA
17 neoplasm MP:0002006 9.93 NKX2-1 PDGFRA STK11 TP63 EGFR KIT
18 respiratory system MP:0005388 9.81 EGFR ENO2 KIT NKX2-1 PDGFRA PTHLH
19 skeleton MP:0005390 9.56 EGFR FGFR1 KIT NKX2-1 PDGFRA PTHLH
20 vision/eye MP:0005391 9.17 EGFR FGFR1 KIT NCAM1 PTHLH STK11

Drugs & Therapeutics for Large Cell Carcinoma

Drugs for Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 388)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
4
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
5
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
9
Armodafinil Approved, Investigational Phase 4 112111-43-0
10
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
11
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
12
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
13
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
14
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
17
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
20 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
21 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
26 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
31 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Central Nervous System Stimulants Phase 4,Phase 2
34 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 1
35 Wakefulness-Promoting Agents Phase 4
36 Antacids Phase 4
37 Anti-Ulcer Agents Phase 4
38
Dexlansoprazole Phase 4 138530-94-6, 103577-45-3 9578005
39 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
40
Proton pump inhibitors Phase 4
41 Interferon-alpha Phase 4,Phase 3,Phase 2
42 interferons Phase 4,Phase 3,Phase 2,Phase 1
43 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
44 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
45 tyrosine Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
46
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
47
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
48
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
49
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
50
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1 216974-75-3

Interventional clinical trials:

(show top 50) (show all 577)
id Name Status NCT ID Phase
1 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4
2 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
3 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4
4 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4
5 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
6 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Active, not recruiting NCT02151149 Phase 4
7 Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load Terminated NCT00977054 Phase 4
8 Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer Withdrawn NCT01353794 Phase 4
9 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3
10 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
11 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
12 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Completed NCT00404924 Phase 3
13 Aldara for the Treatment of Large and/or Multiple sBCC Completed NCT00189280 Phase 3
14 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3
15 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
16 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
17 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3
18 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3
19 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3
20 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3
21 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3
22 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3
23 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3
24 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3
25 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3
26 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3
27 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3
28 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
29 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
30 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3
31 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
32 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
33 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
34 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3
35 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
36 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3
37 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
38 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3
39 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
40 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Completed NCT00312377 Phase 3
41 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3
42 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Completed NCT00262821 Phase 3
43 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3
44 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3
45 Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) Completed NCT00409188 Phase 3
46 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3
47 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
48 A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) Completed NCT00257608 Phase 3
49 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed NCT00079274 Phase 3
50 ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients Recruiting NCT02737501 Phase 3

Search NIH Clinical Center for Large Cell Carcinoma

Cochrane evidence based reviews: carcinoma, large cell

Genetic Tests for Large Cell Carcinoma

Anatomical Context for Large Cell Carcinoma

MalaCards organs/tissues related to Large Cell Carcinoma:

39
Lung, Thyroid, Brain, Thymus, Prostate, Ovary, Small Intestine

Publications for Large Cell Carcinoma

Articles related to Large Cell Carcinoma:

(show top 50) (show all 168)
id Title Authors Year
1
The development of large-cell carcinoma in the wall of a giant bulla complicated by hemorrhage. ( 26964998 )
2016
2
BRAF mutations in sarcomatoid and large cell carcinoma of the lung. ( 27939777 )
2016
3
BRAF mutations in sarcomatoid and large cell carcinoma of the lung-reply. ( 27939780 )
2016
4
Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung. ( 27384989 )
2016
5
Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. ( 26818832 )
2016
6
Close Relation of Large Cell Carcinoma to Adenocarcinoma by Hierarchical Cluster Analysis: Implications for Histologic Typing of Lung Cancer on Biopsies. ( 25789531 )
2015
7
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. ( 25638031 )
2015
8
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. ( 26317919 )
2015
9
Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. ( 25937073 )
2015
10
USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma. ( 25519684 )
2015
11
Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung. ( 26345631 )
2015
12
The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma. ( 26543611 )
2015
13
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. ( 26186355 )
2015
14
A retrospective analysis of the clinicopathological characteristics of large cell carcinoma of the lung. ( 25452802 )
2015
15
Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. ( 25620799 )
2015
16
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. ( 24384807 )
2014
17
Large cell carcinoma on the bullous wall detected in a specimen from a patient with spontaneous pneumothorax: report of a case. ( 25364539 )
2014
18
Treatment outcomes of patients with different subtypes of large cell carcinoma of the lung. ( 25085555 )
2014
19
Large cell carcinoma of lung: On the verge of extinction? ( 25023633 )
2014
20
Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. ( 24221342 )
2014
21
Large-cell carcinoma of the lung: a diagnostic category redefined by immunohistochemistry and genomics. ( 24811836 )
2014
22
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. ( 23196793 )
2013
23
Pulmonary Large Cell Carcinoma Lacking Squamous Differentiation Is Clinicopathologically Indistinguishable From Solid-Subtype Adenocarcinoma. ( 23738762 )
2013
24
Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma. ( 23696935 )
2013
25
Acute small bowel obstruction: a rare initial presentation for the metastasis of the large-cell carcinoma of the lung. ( 22284720 )
2012
26
Mixed squamous and large-cell carcinoma of the lung: a case study and literature review. ( 23174733 )
2012
27
Rhabdoid large cell carcinoma of lung, with illustrative immunohistochemical and molecular findings. ( 22505007 )
2012
28
Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung. ( 22420949 )
2012
29
Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. ( 22031317 )
2011
30
Large cell carcinoma of the lacrimal gland diagnosed by fine needle aspiration biopsy. ( 22132846 )
2011
31
Pulmonary large cell carcinoma mimicking an infected thoracoabdominal aortic aneurysm. ( 21847044 )
2011
32
Primary undifferentiated large cell carcinoma of the lacrimal gland. ( 21276618 )
2011
33
Intussusception of small intestine due to metastasis of large cell carcinoma of the lung with a rhabdoid phenotype. ( 20956201 )
2010
34
Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. ( 20077433 )
2010
35
Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma. ( 20123594 )
2010
36
Results of surgical resection for patients with large cell carcinoma of the lung. ( 20547250 )
2010
37
Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. ( 19287461 )
2009
38
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. ( 19996214 )
2009
39
Large cell carcinoma of the lung: an endangered species? ( 19444077 )
2009
40
Large cell carcinoma of the lung and squamous cell carcinoma of the oropharynx presenting as uveitis. ( 19413230 )
2009
41
Cystic tumors of the right atrium caused by nonbacterial thrombotic endocarditis in a patient with large cell carcinoma. ( 19420823 )
2009
42
Immunohistochemical characterization of a pulmonary large-cell carcinoma in a dog. ( 18587094 )
2008
43
Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. ( 18364444 )
2008
44
Lung large cell carcinoma producing granulocyte-colony-stimulating factor. ( 17184692 )
2007
45
p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas. ( 17665040 )
2007
46
Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. ( 17131342 )
2007
47
Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. ( 17238183 )
2007
48
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. ( 17299065 )
2007
49
Humoral hypercalcemia of malignancy in a patient with large cell carcinoma of the lung: report of case and review of literature. ( 17669716 )
2007
50
Large-cell carcinoma of the lung with a remarkable preoperative elevation of serum carcinoembryonic antigen level. ( 17554998 )
2007

Variations for Large Cell Carcinoma

Expression for Large Cell Carcinoma

Search GEO for disease gene expression data for Large Cell Carcinoma.

Pathways for Large Cell Carcinoma

GO Terms for Large Cell Carcinoma

Biological processes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.99 EGFR FGFR1 KIT NCAM1 PDGFRA
2 phosphorylation GO:0016310 9.99 EGFR FGFR1 KIT PDGFRA ROS1 STK11
3 protein phosphorylation GO:0006468 9.97 EGFR FGFR1 KIT PDGFRA ROS1 STK11
4 positive regulation of cell proliferation GO:0008284 9.96 EGFR FGFR1 KIT PDGFRA PTHLH
5 MAPK cascade GO:0000165 9.8 EGFR FGFR1 KIT NCAM1 PDGFRA
6 epidermis development GO:0008544 9.78 EGFR PTHLH TP63
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.78 EGFR KIT PDGFRA ROS1
8 phosphatidylinositol-mediated signaling GO:0048015 9.76 EGFR FGFR1 KIT PDGFRA
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 FGFR1 KIT PDGFRA
10 positive regulation of MAP kinase activity GO:0043406 9.71 EGFR FGFR1 KIT
11 phosphatidylinositol phosphorylation GO:0046854 9.67 EGFR FGFR1 KIT PDGFRA
12 lung development GO:0030324 9.62 EGFR FGFR1 NKX2-1 PDGFRA
13 anatomical structure formation involved in morphogenesis GO:0048646 9.61 NKX2-1 TP63
14 mast cell degranulation GO:0043303 9.6 CHGA KIT
15 cerebral cortex cell migration GO:0021795 9.58 EGFR NKX2-1
16 Leydig cell differentiation GO:0033327 9.58 NKX2-1 PDGFRA
17 salivary gland morphogenesis GO:0007435 9.57 EGFR FGFR1
18 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.56 EGFR FGFR1 KIT PDGFRA
19 protein autophosphorylation GO:0046777 9.55 EGFR FGFR1 KIT PDGFRA STK11
20 mast cell chemotaxis GO:0002551 9.52 CHGA KIT
21 mast cell cytokine production GO:0032762 9.43 CHGA KIT
22 peptidyl-tyrosine phosphorylation GO:0018108 9.35 EGFR FGFR1 KIT PDGFRA ROS1
23 positive regulation of phospholipase C activity GO:0010863 8.8 FGFR1 KIT PDGFRA

Molecular functions related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.85 EGFR FGFR1 KIT PDGFRA ROS1 STK11
2 protein kinase activity GO:0004672 9.8 EGFR FGFR1 KIT PDGFRA ROS1 STK11
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.56 EGFR FGFR1 KIT PDGFRA
4 protein tyrosine kinase activity GO:0004713 9.55 EGFR FGFR1 KIT PDGFRA ROS1
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 EGFR KIT
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.35 EGFR FGFR1 KIT NCAM1 PDGFRA
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 EGFR FGFR1 KIT PDGFRA ROS1

Sources for Large Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....